CEVEC and CellGenix cooperation leads to expansion of CellGenix cytokine portfolio with CAP®GO Technology-derived TGF-β1 for ex vivo cell culture
- This portfolio expansion is the result of an ongoing collaboration and license agreement between CEVEC and CellGenix for the development and GMP production of selected cytokines for ex vivo cell culture therapy applications using CEVEC’s proprietary CAP®GO technology
- CEVEC’s CAP®GO technology enables CellGenix access to new cytokines and proteins requiring human post-translational modifications not provided by bacterial expression systems
- CellGenix® recombinant human transforming growth factor-beta 1 (rh TGF-β1) is used for the expansion of pluripotent stem cells (PSC) and mesenchymal stem cells (MSC) as well as for the differentiation of T cells into regulatory T cells (Treg cells) and the expansion of Treg cells
- CAP®GO-derived GMP TGF-β1 is planned to become available in the second half of 2018
Cologne and Freiburg, Germany, January 31, 2018
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, is pleased to note that cooperation partner CellGenix, a leading global supplier of GMP raw materials for cell and gene therapy and regenerative medicine, today announced the expansion of its portfolio with the introduction of CAP®GO technology-derived preclinical grade TGF-β1 for ex vivo cell culture applications. After CellGenix® rh HGF, this is the second product originating from this cooperation.